A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PsA / psoriatic arthritis

[Related PubMed/MEDLINE]
Total Number of Papers: 3216
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PsA  (>> Co-occurring Abbreviation)
Long Form:   psoriatic arthritis
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. DMARDs, GVA
2020 A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy. DMARDs, NHS
2020 A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. ---
2020 A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. ADA, csDMARDs, IXE
2020 A Multimodal Eye Assessment in Psoriatic Arthritis Patients sine-Psoriasis: Evidence for a Potential Association with Systemic Inflammation. FP, HC, OSDI, PsO, SD-OCT
2020 A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis. ECM, MMP
2020 A novel treatment for psoriatic arthritis: Janus kinase inhibitors. JAK
2020 A potential inflammatory role of IL-31 in psoriatic arthritis: A correlation with Th17 cytokine profile. CS, IL, IL-17A, qPCR, RORC
2020 A proposal on how to assess the weight of the subjective components of the DAPSA in patients with psoriatic arthritis and comorbid fibromyalgia syndrome. DAPSA, DAPSA-P, FM, ROC
10  2020 Accuracy of Physical Examination to Detect Synovial and Extra-Synovial Pathologies in Psoriatic Arthritis in Comparison to Ultrasonography. MCP, PABAK, PD, PE, PIP, US
11  2020 Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis. IL, MDA, MTX
12  2020 Adherence to Subcutaneous Anti-TNF Treatment in Chronic Inflammatory Rheumatism and Therapeutic Patient Education. anti-TNF, AS, RA, TPE
13  2020 Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. AMP, IMI
14  2020 Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. AA, HADS, IL
15  2020 An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. DMARD, HZ, IRs, MACE, NMSC
16  2020 An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. CI, DAPSA, mMDA, OR
17  2020 An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis. JAK, PsO
18  2020 Analysis by Age Group of Disease Outcomes in Patients with Psoriatic Arthritis: A Cross-Sectional Multicentre Study. ---
19  2020 Anti-cyclic citrullinated peptide antibody in psoriatic arthritis: ameta-analysis of its frequency and association with clinical features. anti-CCP, CI, OR
20  2020 Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data. ESS, PRP
21  2020 Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. HAQ, OMERACT, PROM, PROMIS
22  2020 Apremilast and its role in psoriatic arthritis. DMARDs, TNF-alpha
23  2020 Apremilast to treat oral ulcers in Behcet syndrome. Bsy, PDE4, Ps
24  2020 Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. ---
25  2020 Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound. BMI, FM, GUESS, LEI, MASES, PD, ROC
26  2020 Assessment of serum levels of anti-cyclic citrullinated peptide antibodies in patients with psoriatic arthritis: A cross-sectional study in a Brazilian cohort. CCP
27  2020 Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. DAPSA, MDA, PASS, PsAID, VLDA
28  2020 Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross-sectional, multi-country, observational study. csDMARD
29  2020 Association Between Comorbidities and Quality of Life in Psoriatic Arthritis: Results from a Multicentric Cross-sectional Study. CASPAR, MCS, mRDCI, PCS, QOL
30  2020 Association between Leeds Dactylitis Index and ultrasonographic features: a multicentre study on psoriatic hand dactylitis. GS, LDI-b, PD, PIP
31  2020 Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies. CIs, RRs
32  2020 Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis. ADA, CASPAR, DMARDs, ETN, IFX, RF, TNF
33  2020 Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. ---
34  2020 Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS. ADA, ADAb, HAQ, TNFi
35  2020 Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis. TNFi
36  2020 Association Study between Psoriatic Arthritis and Killer Immunoglobulin-Like Receptor (KIR) Genes: A Meta-Analysis. KIR, OR
37  2020 Associations between human leukocyte antigen C locus polymorphism and psoriatic arthritis in populations of European and Middle Eastern descent: a meta-analysis. HLA, OR
38  2020 At the crossroads of gout and psoriatic arthritis: "psout". ---
39  2020 Atlas of the OMERACT Heel Enthesitis MRI Scoring System (HEMRIS). HEMRIS, HEMRIS, OMERACT, SpA
40  2020 Autoantibodies against specific nuclear antigens are present in psoriatic disease and are diminished by secukinumab. Ab, ANA, DFS70, HCs, Ps
41  2020 Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis. CVD, IA, RA
42  2020 Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement. ERA, JIA
43  2020 Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. RR
44  2020 Birth Outcomes and Disease Activity During Pregnancy in a Prospective Cohort of Women With Psoriatic Arthritis and Ankylosing Spondylitis. aRRs, AS, HAQ, RAPID3
45  2020 Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases. AS, IL-17, SLE, SS, SSc
46  2020 Bristol rheumatoid arthritis fatigue scale is valid in patients with psoriatic arthritis and is associated with overall severe disease and higher comorbidities. CCI, FACIT-F
47  2020 Cancer in adult patients with inflammatory arthritis is associated with high ascending aortic stiffness and left ventricular hypertrophy and diastolic dysfunction. AoSI, AS, CV, LV, RA
48  2020 Cardiovascular Disease in Spondyloarthritides. AS
49  2020 Cardiovascular risk factors are highly overrepresented in Swedish patients with psoriatic arthritis compared with the general population. BMI
50  2020 Cardiovascular risk in psoriatic arthritis, a narrative review. ---
51  2020 Cartilage Degradation in Psoriatic Arthritis Is Associated With Increased Synovial Perfusion as Detected by Magnetic Resonance Imaging. DCE-MRI, dGEMRIC, DIP, JSW, MCP, PIP, PsAMRIS, RA, TCT
52  2020 Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. CZP
53  2020 Challenges in the clinical diagnosis of psoriatic arthritis. ---
54  2020 Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A. cyno, IL, RA, TNF
55  2020 Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. DLQI, EQ VAS, WPAI
56  2020 Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients. AS, IGRA, LTBI, NNH, RA
57  2020 Circulating microRNAs in extracellular vesicles as potential biomarkers for psoriatic arthritis in patients with psoriasis. EVs, PsC
58  2020 Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life. BL, CZP, PASI, PsO
59  2020 Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome. AS, LVM, MetS, RA
60  2020 Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. DI, DMARDs, ES, PF, PROMs, RCTs, SF-36 PCS
61  2020 Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin. AS, NW, SpA, TNF, TNFi
62  2020 Combined manual and automated immunophenotypisation identified disease-specific peripheral blood immune subpopulations in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. AS, RA
63  2020 Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. aHR, AS, csDMARD, MTX, RA, SpA, TNFi
64  2020 Comparative results of the implementation in daily practice of an evaluation checklist for patients with axial spondyloarthritis and psoriatic arthritis. axSpA
65  2020 Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. CIs, HRs, IL, IRs, PsO, TNF
66  2020 Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases. DMARDs, PsO, RA, TNFi
67  2020 Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). ACR, DAPSA, DMARD, HAQ, LEF, MDA, MTX, PASDAS, PSAID, SF-12
68  2020 Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. MCP, MRI, OMERACT, PIP, PsAMRIS, SRM, StdC, TC, TICOPA, US
69  2020 Comparing the patient reported physical function outcome measures in a real-life international cohort of patients with psoriatic arthritis. HAQ-DI, PCS12, PROMs, PsAID-FC
70  2020 Comparison of bone structure and microstructure in the metacarpal heads between patients with psoriatic arthritis and healthy controls: an HR-pQCT study. HR-pQCT, MCH, vBMD
71  2020 Comparison of carotid artery ultrasound and Framingham risk score for discriminating coronary artery disease in patients with psoriatic arthritis. CAD, CCTA, CIMT, CV, FRS, O-CAD, TPA, US
72  2020 Comparison of Hospital Anxiety and Depression Scale (HADS) and Zung Self-Rating Anxiety/Depression Scale (SAS/SDS) in Evaluating Anxiety and Depression in Patients with Psoriatic Arthritis. HADS, PGA, SAS/SDS
73  2020 Complementary and Alternative Medicine Use in Psoriatic Arthritis Patients: a Review. CAM
74  2020 Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. DAPSA, mCPDAI, PASDAS
75  2020 Concentric left ventricular remodelling is associated with subclinical systolic dysfunction in patients with psoriatic arthritis. CASPAR, CI, LV, LVSD, OR
76  2020 Conducting research in psoriatic arthritis: the emerging role of patient research partners. PRP
77  2020 Construct validity of the ASAS health index in psoriatic arthritis: a cross-sectional analysis. ASAS-HI, AUC, DAPSA, PsAID
78  2020 Content validity of psoriatic arthritis screening questionnaires: systematic review. PROMs, PsO
79  2020 Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis. MS
80  2020 Correlation of serum protein biomarkers with disease activity in psoriatic arthritis. CASPAR, MBDA, RA, UCSD
81  2020 Correlations of fatigue in Danish patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis. axSpA, HAQ, MDI, MOS, PROs, RA, WPAI
82  2020 Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany. DMARDs, HAQ, ICERs
83  2020 Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. bDMARD, BSC, CEAs, IL-17A, PsARC, QALYs
84  2020 Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States. ACR, ADRs, csDMARD, IR, NICE, TNFi
85  2020 Cross-cultural validation and psychometric properties of the Brazilian Portuguese version of the Psoriasis Epidemiology Screening Tool (PEST-bp). DLQI, PEST
86  2020 Curcumin mediates attenuation of pro-inflammatory interferon gamma and interleukin 17 cytokine responses in psoriatic disease, strengthening its role as a dietary immunosuppressant. CD, IFN, IL, NK, STAT
87  2020 Current knowledge on autoantigens and autoantibodies in psoriasis. ---
88  2020 Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project. ---
89  2020 Current understanding and future perspectives of brain-heart-kidney axis in psoriatic arthritis. CVD, MRI
90  2020 DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study. CIMT, CP, CV, CVD, DAPSA
91  2020 Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker? ---
92  2020 Defining Pre-Clinical Psoriatic Arthritis in an Integrated Dermato-Rheumatology Environment. ACPA, PsO
93  2020 Delphi-based recommendations for the management of cardiovascular comorbidities in patients with psoriatic arthritis and moderate-to-severe psoriasis. CV, MS-PSO
94  2020 Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation. bDMARDs
95  2020 Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. DAPSA, PR
96  2020 Development and initial validation of a questionnaire to assess facilitators and barriers to physical activity for patients with rheumatoid arthritis, axial spondyloarthritis and/or psoriatic arthritis. axSpA, IA, mHAQ, PA, RA
97  2020 Development and validation of psoriatic arthritis switch quality assessment tool (PASQAL) - an outcomes measurement tool to assess the quality of biologic switch decisions in psoriatic arthritis. PASQAL
98  2020 Development of a Modified Psoriatic Arthritis Disease Activity Score Using the Medical Outcomes Study Short Form 12 as a Measure of Quality of Life. mPASDAS, PASDAS, SF-36
99  2020 Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis. IL
100  2020 Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis. AUC